Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa

Author:

Salaam-Dreyer Zubeida1,Streicher Elizabeth M.2,Sirgel Frederick A.2,Menardo Fabrizio34,Borrell Sonia34,Reinhard Miriam34,Doetsch Anna34,Cudahy Patrick G. T.5,Mohr-Holland Erika6,Daniels Johnny6,Dippenaar Anzaan7ORCID,Nicol Mark P.8,Gagneux Sebastien34ORCID,Warren Robin M.2,Cox Helen19ORCID

Affiliation:

1. Division of Medical Microbiology, Department of Pathology, University of Cape Town, Cape Town, South Africa

2. DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/SAMRC Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa

3. Swiss Tropical and Public Health Institute, Basel, Switzerland

4. University of Basel, Basel, Switzerland

5. Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA

6. Médecins Sans Frontières, Khayelitsha, Cape Town, South Africa

7. Tuberculosis Omics Research Consortium, Family Medicine and Population Health, Institute of Global Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

8. Division of Infection and Immunity, School of Biomedical Sciences, University of Western Australia, Perth, Australia

9. Institute of Infectious Disease and Molecular Medicine and Wellcome Centre for Infectious Disease Research, University of Cape Town, Cape Town, South Africa

Abstract

Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aimed to compare RMR-TB with multidrug-resistant TB (MDR-TB) in a setting with high TB, RR-TB, and HIV burdens.

Funder

South African National Research Foundation

Swiss National Science Foundation

The Wellcome Trust

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3